Viracta Therapeutics is laying off 23% of its employees, the company announced Wednesday in a press release. The clinical-stage precision oncology company previously noted the layoff in a July 29 Securities and Exchange Commission filing, stating the forced reduction would be complete this month. Viracta did not specify how many employees it was laying off, but a May 9 SEC filing noted the company had 40 full-time employees as of March 31, including 30 in R&D.
According to the press release, Viracta has aligned its resources to prioritize its Epstein-Barr virus-positive (EBV+) lymphoma program. The company noted it received positive feedback from a meeting with the U.S. Food and Dr-g Administration, giving clarity on a potential regulatory path to initial registration of nana-val in patients with relapsed or refractory EBV+ peripheral T cell lymphoma.
https://www.globenewswire.com/news-release/2024/08/14/2929921/0/en/Viracta-Therapeutics-Announces-Positive-Data-from-the-Phase-2-NAVAL-1-Trial-Regulatory-Progress-and-Updated-Nana-val-Clinical-Development-Plan.html